![Pieter de Geus](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Yoav Hineman | M | - |
Prothya Biosolutions Belgium BV
![]() Prothya Biosolutions Belgium BV BiotechnologyHealth Technology Prothya Biosolutions Belgium BV is a Belgian company that was founded in 1997. The private company is based in Brussels, Belgium. The company manufactures plasma and pharmaceutical raw materials and operate as blood transfusion centers and organ banks. | 4 ans |
Frank P. Luyten | M | 69 |
Neuroplast BV
![]() Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | 3 ans |
Marcel Kloosterman | M | - |
Neuroplast BV
![]() Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | - |
Michel Briejer | M | - |
Alveron Pharma BV
![]() Alveron Pharma BV Pharmaceuticals: MajorHealth Technology Alveron Pharma BV is a Dutch company that develops cyclodextrin-based drugs. The company is based in Nijmegen, Netherlands. The company was founded in 2019. Ben Nichols has been the CEO of the company since 2019. | - |
Ben Nichols | M | - |
Alveron Pharma BV
![]() Alveron Pharma BV Pharmaceuticals: MajorHealth Technology Alveron Pharma BV is a Dutch company that develops cyclodextrin-based drugs. The company is based in Nijmegen, Netherlands. The company was founded in 2019. Ben Nichols has been the CEO of the company since 2019. | 5 ans |
Bud Scholl | M | 64 |
Prothya Biosolutions Belgium BV
![]() Prothya Biosolutions Belgium BV BiotechnologyHealth Technology Prothya Biosolutions Belgium BV is a Belgian company that was founded in 1997. The private company is based in Brussels, Belgium. The company manufactures plasma and pharmaceutical raw materials and operate as blood transfusion centers and organ banks. | 4 ans |
Samuel Gerssen | M | - |
Alveron Pharma BV
![]() Alveron Pharma BV Pharmaceuticals: MajorHealth Technology Alveron Pharma BV is a Dutch company that develops cyclodextrin-based drugs. The company is based in Nijmegen, Netherlands. The company was founded in 2019. Ben Nichols has been the CEO of the company since 2019. | - |
Nir Epstein | M | 54 |
Prothya Biosolutions Belgium BV
![]() Prothya Biosolutions Belgium BV BiotechnologyHealth Technology Prothya Biosolutions Belgium BV is a Belgian company that was founded in 1997. The private company is based in Brussels, Belgium. The company manufactures plasma and pharmaceutical raw materials and operate as blood transfusion centers and organ banks. | 3 ans |
Johannes de Munter | M | - |
Neuroplast BV
![]() Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | 8 ans |
Marianne van der Steen | M | - |
Neuroplast BV
![]() Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | - |
Wim Brouwer | M | - |
Neuroplast BV
![]() Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | - |
Alex Zwiers | M | - |
Alveron Pharma BV
![]() Alveron Pharma BV Pharmaceuticals: MajorHealth Technology Alveron Pharma BV is a Dutch company that develops cyclodextrin-based drugs. The company is based in Nijmegen, Netherlands. The company was founded in 2019. Ben Nichols has been the CEO of the company since 2019. | - |
Yuval Cohen | M | - |
Prothya Biosolutions Belgium BV
![]() Prothya Biosolutions Belgium BV BiotechnologyHealth Technology Prothya Biosolutions Belgium BV is a Belgian company that was founded in 1997. The private company is based in Brussels, Belgium. The company manufactures plasma and pharmaceutical raw materials and operate as blood transfusion centers and organ banks. | 4 ans |
Pierre Falcou | M | - |
Prothya Biosolutions Belgium BV
![]() Prothya Biosolutions Belgium BV BiotechnologyHealth Technology Prothya Biosolutions Belgium BV is a Belgian company that was founded in 1997. The private company is based in Brussels, Belgium. The company manufactures plasma and pharmaceutical raw materials and operate as blood transfusion centers and organ banks. | 4 ans |
Lamb Christopher | M | - |
Prothya Biosolutions Belgium BV
![]() Prothya Biosolutions Belgium BV BiotechnologyHealth Technology Prothya Biosolutions Belgium BV is a Belgian company that was founded in 1997. The private company is based in Brussels, Belgium. The company manufactures plasma and pharmaceutical raw materials and operate as blood transfusion centers and organ banks. | 4 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Pays-Bas | 9 | 60,00% |
Belgique | 6 | 40,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Pieter de Geus
- Réseau Personnel